Biogen price target raised to $308 from $305 at Canaccord

Canaccord raised the firm’s price target on Biogen to $308 from $305 and keeps a Buy rating on the shares. The firm said there were no major surprises in the quarter, and are encouraged by signs of solid execution. On the stock, they continue to believe three factors remain key in the near to mid-term; the Skyclarys and Zurzuvae launches, and keeping a watch on a potential inflection on Leqembi, continued defense on the rest of the product base which appear to be holding up well, and further cost optimization.